Reta Glp 3 (Retatrutide) 40mg Research Peptide
Retatrutide is a GLP-1/GIP/glucagon triple receptor agonist peptide developed by Eli Lilly. This 40mg vial is our largest single-vial quantity, designed for extended or multi-model research protocols. Purity ≥99%, HPLC and MS/MS verified per batch.
Research Background
Retatrutide’s simultaneous activation of GLP-1R, GIPR, and GCGR produces a distinct metabolic profile compared to dual agonists. Phase 2 trial data (NEJM, 2023) demonstrated up to 24.2% body weight reduction over 48 weeks and significant hepatic fat reduction, supporting research into obesity, NAFLD/MASH, and insulin resistance models. Phase 3 TRIUMPH trials ongoing as of 2026.
For a full overview of retatrutide’s mechanism, clinical trial data, dosage reference, and comparison with tirzepatide, see our Retatrutide Peptide Research Guide. Also available in 10mg, 20mg, and 30mg vials.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 40mg per vial
- Storage: −20°C, protected from light
- CAS Number: 2381272-12-2
Certificate of Analysis
Third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
